Satya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA
Abstract title Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors Poster number A099 Session Poster Session A Session date and time Thursday, October 12 | 12:30 pm-4:00 pm Session location Level 2, Exhibit Hall D Abstract title: Best in class, potent, SOS1 inhibitors demonstrate single agent activity […]
